Additionally, it aimed to identify miRNA expression differences between MPO- and PR3-positive AAG-GN cases and correlate the molecular data with clinical and histologic markers of disease activity to improve diagnostic accuracy. This evidence concerns the gene PRTN3 and ganglioneuroma.